2-Methyl-6-(prop-2-enylamino)pyridine-4-carboxylic acid | 900864-64-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-Methyl-6-(prop-2-enylamino)pyridine-4-carboxylic acid
• 英文别名: 2-methyl-6-(prop-2-enylamino)pyridine-4-carboxylic acid
• CAS: 900864-64-4
• 化学式: C₁₀H₁₂N₂O₂
• 分子量: 192.217
• InChiKey: ZJOBYSWSBUZEEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-Methyl-6-(prop-2-enylamino)pyridine-4-carboxylic acid 、 C₃₁H₃₈N₂O₄ 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application

  摘要：

  A series of macrocyclic peptidic BACE-1 inhibitors was designed. While potency on BACE-1 was rather high, the first set of compounds showed poor brain permeation and high efflux in the MDRI-MDCK assay. The replacement of the secondary benzylamino group with a phenylcyclopropylamino group maintained potency on BACE-1, while P-glycoprotein-mediated efflux was significantly reduced and brain permeation improved. Several compounds from this series demonstrated acute reduction of Ab in human APP-wildtype transgenic (APP51/16) mice after oral administration. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.092

文献信息

• Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application
  作者：Andreas Lerchner、Rainer Machauer、Claudia Betschart、Siem Veenstra、Heinrich Rueeger、Clive McCarthy、Marina Tintelnot-Blomley、Anne-Lise Jaton、Sabine Rabe、Sandrine Desrayaud、Albert Enz、Matthias Staufenbiel、Paolo Paganetti、Jean-Michel Rondeau、Ulf Neumann

  DOI：10.1016/j.bmcl.2009.11.092

  日期：2010.1

  A series of macrocyclic peptidic BACE-1 inhibitors was designed. While potency on BACE-1 was rather high, the first set of compounds showed poor brain permeation and high efflux in the MDRI-MDCK assay. The replacement of the secondary benzylamino group with a phenylcyclopropylamino group maintained potency on BACE-1, while P-glycoprotein-mediated efflux was significantly reduced and brain permeation improved. Several compounds from this series demonstrated acute reduction of Ab in human APP-wildtype transgenic (APP51/16) mice after oral administration. (C) 2009 Elsevier Ltd. All rights reserved.